175 related articles for article (PubMed ID: 19934371)
1. Delayed treatment with plasminogen activator inhibitor-1 decoys reduces tubulointerstitial fibrosis.
Gonzalez J; Klein J; Chauhan SD; Neau E; Calise D; Nevoit C; Chaaya R; Miravete M; Delage C; Bascands JL; Schanstra JP; Buffin-Meyer B
Exp Biol Med (Maywood); 2009 Dec; 234(12):1511-8. PubMed ID: 19934371
[TBL] [Abstract][Full Text] [Related]
2. Endogenous urokinase lacks antifibrotic activity during progressive renal injury.
Yamaguchi I; Lopez-Guisa JM; Cai X; Collins SJ; Okamura DM; Eddy AA
Am J Physiol Renal Physiol; 2007 Jul; 293(1):F12-9. PubMed ID: 17356128
[TBL] [Abstract][Full Text] [Related]
3. Plasmin is not protective in experimental renal interstitial fibrosis.
Edgtton KL; Gow RM; Kelly DJ; Carmeliet P; Kitching AR
Kidney Int; 2004 Jul; 66(1):68-76. PubMed ID: 15200414
[TBL] [Abstract][Full Text] [Related]
4. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy.
Yang J; Liu Y
Am J Physiol Renal Physiol; 2003 Feb; 284(2):F349-57. PubMed ID: 12529273
[TBL] [Abstract][Full Text] [Related]
5. [Modulation of aberrant extracellular matrix degradation systems by astragali radix and angelicae sinensis radix decoction (A&A) in interstitial fibrotic kidney].
Meng L; Liao A; Qu L; Tang J; Li X
Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(1):79-84. PubMed ID: 22741467
[TBL] [Abstract][Full Text] [Related]
6. Tissue-type plasminogen activator deficiency exacerbates cholestatic liver injury in mice.
Wang H; Zhang Y; Heuckeroth RO
Hepatology; 2007 Jun; 45(6):1527-37. PubMed ID: 17538930
[TBL] [Abstract][Full Text] [Related]
7. PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA.
Wang H; Zhang Y; Heuckeroth RO
FEBS Lett; 2007 Jun; 581(16):3098-104. PubMed ID: 17561000
[TBL] [Abstract][Full Text] [Related]
8. Suppression of renal tubulointerstitial fibrosis by small interfering RNA targeting heat shock protein 47.
Xia Z; Abe K; Furusu A; Miyazaki M; Obata Y; Tabata Y; Koji T; Kohno S
Am J Nephrol; 2008; 28(1):34-46. PubMed ID: 17890856
[TBL] [Abstract][Full Text] [Related]
9. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction.
Oda T; Jung YO; Kim HS; Cai X; López-Guisa JM; Ikeda Y; Eddy AA
Kidney Int; 2001 Aug; 60(2):587-96. PubMed ID: 11473641
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice.
Wang H; Vohra BP; Zhang Y; Heuckeroth RO
Hepatology; 2005 Nov; 42(5):1099-108. PubMed ID: 16250054
[TBL] [Abstract][Full Text] [Related]
11. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice.
Matsuo S; López-Guisa JM; Cai X; Okamura DM; Alpers CE; Bumgarner RE; Peters MA; Zhang G; Eddy AA
Kidney Int; 2005 Jun; 67(6):2221-38. PubMed ID: 15882265
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice.
Moriwaki H; Stempien-Otero A; Kremen M; Cozen AE; Dichek DA
Circ Res; 2004 Sep; 95(6):637-44. PubMed ID: 15297377
[TBL] [Abstract][Full Text] [Related]
13. Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy.
Zhang G; Kim H; Cai X; López-Guisa JM; Alpers CE; Liu Y; Carmeliet P; Eddy AA
J Am Soc Nephrol; 2003 May; 14(5):1254-71. PubMed ID: 12707394
[TBL] [Abstract][Full Text] [Related]
14. MMP-2 inhibition reduces renal macrophage infiltration with increased fibrosis in UUO.
Nishida M; Okumura Y; Ozawa S; Shiraishi I; Itoi T; Hamaoka K
Biochem Biophys Res Commun; 2007 Mar; 354(1):133-9. PubMed ID: 17210124
[TBL] [Abstract][Full Text] [Related]
15. TGF-beta1 siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction.
Hwang M; Kim HJ; Noh HJ; Chang YC; Chae YM; Kim KH; Jeon JP; Lee TS; Oh HK; Lee YS; Park KK
Exp Mol Pathol; 2006 Aug; 81(1):48-54. PubMed ID: 16443218
[TBL] [Abstract][Full Text] [Related]
16. Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice.
Higashi K; Oda T; Kushiyama T; Hyodo T; Yamada M; Suzuki S; Sakurai Y; Miura S; Kumagai H
Nephrology (Carlton); 2010 Apr; 15(3):327-35. PubMed ID: 20470302
[TBL] [Abstract][Full Text] [Related]
17. Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis.
Hewitson TD; Ho WY; Samuel CS
Endocrinology; 2010 Oct; 151(10):4938-48. PubMed ID: 20826562
[TBL] [Abstract][Full Text] [Related]
18. Complement C5 mediates experimental tubulointerstitial fibrosis.
Boor P; Konieczny A; Villa L; Schult AL; Bücher E; Rong S; Kunter U; van Roeyen CR; Polakowski T; Hawlisch H; Hillebrandt S; Lammert F; Eitner F; Floege J; Ostendorf T
J Am Soc Nephrol; 2007 May; 18(5):1508-15. PubMed ID: 17389734
[TBL] [Abstract][Full Text] [Related]
19. Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade.
Okada H; Watanabe Y; Kikuta T; Kobayashi T; Kanno Y; Sugaya T; Suzuki H
J Am Soc Nephrol; 2004 Sep; 15(9):2404-13. PubMed ID: 15339989
[TBL] [Abstract][Full Text] [Related]
20. Serine proteases, inhibitors and receptors in renal fibrosis.
Eddy AA
Thromb Haemost; 2009 Apr; 101(4):656-64. PubMed ID: 19350108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
